20 results
D
n08bk551k fow02
7 Oct 22
$16.19 mm in equity / options / securities to be acquired, sold $6.65 mm, 5 investors
5:32pm
8-K
EX-10.1
jwd 3z0umt
24 May 22
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
4:05pm
10-K
2bbxwwwy
22 Sep 21
Annual report
4:45pm
10-Q
nzuuu7hr s1yw3fcn
21 Jun 21
Quarterly report
5:06pm
424B4
68kh59h3334rvh
10 May 21
Prospectus supplement with pricing info
4:52pm
S-1/A
f8l822w qgnxkusxn6
26 Apr 21
IPO registration (amended)
4:38pm
S-1
3brk42p
1 Apr 21
IPO registration
5:19pm
S-1
EX-10.4
0atqp8jjcqobviewy
1 Apr 21
IPO registration
5:19pm
DRS/A
i8mujso3hgtho
12 Mar 21
Draft registration statement (amended)
12:00am
DRS/A
EX-10.4
4t0spaxb
12 Mar 21
Draft registration statement (amended)
12:00am
DRS
dxyvk7qc fmbvl
29 Jan 21
Draft registration statement
12:00am
D
et2oneu45fi0
25 Jun 20
$5.25M in equity, sold $3M, 1 investor
3:30pm
- Prev
- 1
- Next